{"filing":{"accession_number":"0001628280-26-039818","cik":"0001655759","ticker":"ARVN","company_name":"ARVINAS, INC.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"arvn-20260602.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026039818/arvn-20260602.htm"},"events":[{"id":7610,"run_id":6691,"accession_number":"0001628280-26-039818","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Arvinas announced a strategic re-prioritization of its pipeline following a strategic review, halting internal development of ARV-806 beyond Phase 1 monotherapy and seeking out-licensing for further clinical trials. This represents a material change in the company's development strategy and resource allocation affecting investor expectations regarding pipeline advancement and cash burn.","company_name":"ARVINAS, INC.","ticker":"ARVN","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3750,"accession_number":"0001628280-26-039818","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Arvinas disclosed a strategic re-prioritization of its pipeline following a strategic review, specifically announcing plans to halt internal development of ARV-806 beyond Phase 1 monotherapy and seek out-licensing for further clinical trials. This represents a material change in the company's development strategy and resource allocation that would affect investor expectations regarding pipeline advancement and cash burn, though it does not fit neatly into more specific categories like ma_activity (no acquisition/disposition) or material_impairment (no asset write-down disclosed).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:44:16.322566+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":7611,"run_id":6691,"accession_number":"0001628280-26-039818","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"summary":"Arvinas furnished an investor presentation for use at the Jefferies Global Healthcare Conference and other investor meetings as a Regulation FD disclosure. This is a routine administrative disclosure of presentation materials for investor communications with no substantive business or operational impact.","company_name":"ARVINAS, INC.","ticker":"ARVN","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3749,"accession_number":"0001628280-26-039818","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This is a Regulation FD disclosure of an investor presentation to be used at the Jefferies Global Healthcare Conference and other investor meetings. The filing is purely procedural—furnishing a presentation document for investor communications—and contains no substantive business, financial, or operational disclosures. The boilerplate language explicitly disclaims filing status and incorporation by reference, indicating this is a routine administrative disclosure rather than a material event affecting the registrant's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:44:16.322566+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3749,"accession_number":"0001628280-26-039818","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This is a Regulation FD disclosure of an investor presentation to be used at the Jefferies Global Healthcare Conference and other investor meetings. The filing is purely procedural—furnishing a presentation document for investor communications—and contains no substantive business, financial, or operational disclosures. The boilerplate language explicitly disclaims filing status and incorporation by reference, indicating this is a routine administrative disclosure rather than a material event affecting the registrant's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:44:16.322566+00:00","company_name":"ARVINAS, INC.","ticker":"ARVN","filing_date":"2026-06-02"},{"id":3750,"accession_number":"0001628280-26-039818","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Arvinas disclosed a strategic re-prioritization of its pipeline following a strategic review, specifically announcing plans to halt internal development of ARV-806 beyond Phase 1 monotherapy and seek out-licensing for further clinical trials. This represents a material change in the company's development strategy and resource allocation that would affect investor expectations regarding pipeline advancement and cash burn, though it does not fit neatly into more specific categories like ma_activity (no acquisition/disposition) or material_impairment (no asset write-down disclosed).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:44:16.322566+00:00","company_name":"ARVINAS, INC.","ticker":"ARVN","filing_date":"2026-06-02"}]}